UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 108

of 'Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects'

108
TI
Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
AU
Park SG, Chung CH, Park CY
SO
Tumori. 2011;97(6):794.
 
There are no effective conventional systemic cytotoxic therapies for patients with unresectable or advanced hepatocellar carcinoma (HCC). Sorafenib, an oral multi-targeted tyrosine kinase inhibitor, was recently approved for the treatment of patients with HCC. Sorafenib is generally well tolerated and has an acceptable toxicity profile.Gastrointestinal perforation is a rare adverse event. We present a case of transverse colon perforation during sorafenib therapy for advanced HCC. A 68-year-old woman with advanced HCC was treated with sorafenib. Eight weeks later the patient presented with the sudden onset of sharp abdominal pain. Emergency surgery was performed for panperitonitis and a perforation involving the transverse colon.
AD
Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea.
PMID